68Ga-PSMA HBED-PET/CT, Prostate Cancer
Conditions
Keywords
68Ga-PSMA, HBED-PET/CT, biochemical relapse, prostate cancer, radically treated
Brief summary
Single-center, prospective, diagnostic trial in radically treated patients with biochemical recurrence of prostate cancer. Patients with radically treated prostate cancer with biochemical relapse and negativity of all traditional morphological and functional imaging (transrectal ultrasound, bone scan, 18F-FMC PET/CT, CT/MRI) or doubtful imaging of 2-deoxy-2-\[fluorine-18\] (18F)-fluoromethylcholine (FMC) PET/CT will receive a Gallio-68 (68Ga)- Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) scan.
Detailed description
Single-center, prospective, diagnostic trial. The primary objective of this study is to evaluate the sensitivity of 68Ga-PSMA PET /CT defined as the ratio between the number of 68Ga-PSMA PET /CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging. The secondary objectives are: * Sensitivity for different Prostatic Specific Antigen (PSA) values (ranges) * Sensitivity for different lesion sites * Treatment response assessment with a second PET * False positives detection during Follow Up (FUP) (with other standard methods and eventually optional biopsy) for patient without any treatment * safety 67 evaluable patients will be injected with 100-200 megabecquerel (MBq) 68Ga-PSMA intravenously
Interventions
DRUG68Ga- PSMA
100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
Sponsors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must have histologically or cytologically confirmed prostate cancer 2. Male, aged \>18 years. 3. Radical treatment for prostate cancer (radiotherapy or surgery) 4. 18F-FMC PET/CT negative or doubtful 5. Negativity of all the other traditional morphological and functional imaging (transrectal ultrasound, bone scan, CT/MRI) 6. Patients with PSA progression defined as PSA ≥ 1,0 ng/mL and/or PSA rising defined as 2 subsequent values showing PSA increase at least 1 week apart. 7. Male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter 8. Participant is willing and able to give informed consent for participation in the study.
Exclusion criteria
1. No hormonotherapy in the last 6 months 2. No radiotherapy in the last 6 months. 3. Patients with PSA \< 1.0 ng/ml 4. Participation in another clinical trial with any investigational agents within 30 days prior to study screening. 5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Study Agent. 6. Medical or psychological conditions that would not permit the subject to complete to sign informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the ratio between the number of 68Ga-PSMA PET/CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging | up to 24 months | the ratio between the number of 68Ga-PSMA PET/CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity for different lesion sites | up to 24 months | Sensitivity of 68Ga- PSMA PET/CT for different lesion sites |
| PSA decrease: the receiver operating characteristic (ROC) curves generated by plotting sensitivity versus 1-specificity. Youden's index will be used for determining cut-off value between pos and neg 68Ga-PSMA PET/CT findings | up to 24 months | for patients that will start an anticancer treatment: evaluate the predictive role of 68Ga- PSMA PET/CT on early response to therapy (hormonotherapy, abiraterone, enzalutamide) taking PSA decrease as a reference. |
| Sensitivity for different PSA values (ranges) | up to 24 months | Sensitivity of 68Ga- PSMA PET/CT for different PSA values (ranges) |
| number of treated patients experiencing grade 1 to 4 adverse events | up to 24 months | number of treated patients undergoing grade 1 to 4 adverse events evaluated according to CTCAE v.4.0 |
| percentage of treated patients experiencing grade 1 to 4 adverse events | up to 24 months | percentage of treated patients experiencing grade 1 to 4 adverse events |
| Evaluation of the concordance between 68Ga- PSMA PET/CT and PET/CT or the others standard methods, performed by the Cohen's kappa coefficient. | up to 24 months | for patient without any treatment: evaluate the concordance between 68Ga- PSMA PET/CT and other standard methods and eventually optional biopsy |
Countries
Italy
Outcome results
None listed